Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging.

Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Abstract Text:

Shalender Bhasin,Olga M Calof,Thomas W Storer,Martin L Lee,Norman A Mazer,Ravi Jasuja,Victor M Montori,Wenqing Gao,James T Dalton,

Several regulatory concerns have hindered development of androgens as anabolic therapies, despite unequivocal evidence that testosterone supplementation increases muscle mass and strength in men; it induces hypertrophy of type I and II muscle fibers, and increases myonuclear and satellite cell number. Androgens promote differentiation of mesenchymal multipotent cells into the myogenic lineage and inhibit their adipogenic differentiation, by facilitating association of androgen receptors with beta-catenin and activating T-cell factor 4. Meta-analyses indicate that testosterone supplementation increases fat-free mass and muscle strength in HIV-positive men with weight loss, glucocorticoid-treated men, and older men with low or low-normal testosterone levels. The effects of testosterone on physical function and outcomes important to patients have not, however, been studied. In older men, increased hematocrit and increased risk of prostate biopsy and detection of prostate events are the most frequent, testosterone-related adverse events. Concerns about long-term risks have restrained enthusiasm for testosterone use as anabolic therapy. Selective androgen-receptor modulators that are preferentially anabolic and that spare the prostate hold promise as anabolic therapies. We need more studies to determine whether testosterone or selective androgen-receptor modulators can induce meaningful improvements in physical function and patient-important outcomes in patients with physical dysfunction associated with chronic illness or aging.

Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Publishing Authors By Initials

S Bhasin,OM Calof,TW Storer,ML Lee,NA Mazer,R Jasuja,VM Montori,W Gao,JT Dalton,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Journal Published:

PUBLICATION TYPE: Review

Journal: Nature clinical practice. Endocrinology & metaboli

VOLUME: 2

Page Numbers: 146-59

Journal Abbreviation:

ISSN: 1745-8366

DAY: 19

MONTH: Mar

YEAR: 2006

Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101261798

Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging.

AFFILIATION: Boston University School of Medicine, Boston, MA 02118, USA. bhasin@bu.edu

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Nat Clin Pract Endocrinol Meta

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging Related Publications

• 7H-dibenzo[c,g]carbazole metabolism by the mouse and human CYP1 family of enzymes.
• A ligand-based approach to identify quantitative structure-activity relationships for the androgen receptor.
• Archaeology: pieces of the puzzle.
• Boosting morale and improving performance in the nursing setting.
• Children with a TV in their bedroom at higher risk for being overweight.
• Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
• Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design.
• Demand and supply of bone allograft and the role of orthopaedic surgeons.
• Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging.
• Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs).
• Flavor Processing: Perceptual and Cognitive Factors in Multi-modal Integration.
• Geology: mine games.
• Hepatocyte-specific Gclc deletion leads to rapid onset of steatosis with mitochondrial injury and liver failure.
• IFN-gamma acts directly on activated CD4+ T cells during mycobacterial infection to promote apoptosis by inducing components of the intracellular apoptosis machinery and by inducing extracellular proapoptotic signals.
• Improving measurement of normative beliefs involving smoking among adolescents.
• In vivo metabolism and final disposition of a novel nonsteroidal androgen in rats and dogs.
• Interaction between the catalytic and modifier subunits of glutamate-cysteine ligase.
• Laws under review for fossils on native land.
• Low-V(pi) electro-optic modulator with a high-microbeta chromophore and a constant-bias field.
• Numerical modeling of nasal obstruction and endoscopic surgical intervention: outcome to airflow and olfaction.
• Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands.
• Progress in development of liver fluke vaccines.
• Proposal raises bones of contention.
• Serological response to hepatitis E virus genotype 3 infection: IgG quantitation, avidity, and IgM response.
• Stereoselective reductase-catalysed deoxygenation of sulfoxides in aerobic and anaerobic bacteria.
• The Levonorgestrel-releasing Intrauterine System: An Updated Review of the Contraceptive and Noncontraceptive Uses.
• Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations.
• US university finds use for Air Force research reactor.
• US warms to carbon sequestration research.
• Veterinary poisons information service.